Boswellinic acids

Boswellinic acids Leukotrienes appear to play a special role as inflammation mediators in the pathogenesis of PBC they also correlate closely with the increase in cholestasis-indicating enzymes. Boswellinic acids are selective non-redox inhibitors of 5-lipoxygen-ase and therefore inhibit leukotriene biosynthesis. So far, they have not been used in PBC treatment. Based on existing pharmacological data, their application should now be considered. 

Boswellinic acids The previous proposal regarding Boswellinic acids also applies to the treatment of PSC (s. p. 652), particularly as this substance has already been used with some success in patients with ulcerative colitis. 

Boswellinic acids are seen as selective non-redox inhibitors of leu-kotriene biosynthesis. Leukotrienes are mediators of inflammation. Boswellic adds proved to be antiphlogistic, hepatoprotective and immunosuppressive in their impact (H.P.T. Ammon et at, 1991). Although there has been no therapeutic application in hepatology up to now, it is likely that future discussion will focus on this pharmacologically interesting group of substances, (s. pp 652, 659)... 

---

See also in sourсe #XX -- [ , , ]

---